About: Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.76 (-2.84%)
GALT NASDAQ Galectin Therapeutics Inc
Galectin Therapeutics Inc share price
GALT price activity
Last Price
$3.760
Change (24hr)
-0.11 USD (-2.84%)
Volume
78.57K
Volume (4w avg)
-
Open
$3.84
Day Range
$3.76 - $3.84
Previous Close
$3.87
Last Trade
13 Oct, 4:20 pm GMT+0
Delayed
13 Oct, 4:20 pm GMT+0
GALT price performance
Delayed
13 Oct, 4:20 pm GMT+0
GALT Market Signals